Savadjian André J, Taicher Brad M, La Jong Ok, Podgoreanu Mihai, Miller Timothy E, McCartney Sharon, Raghunathan Karthik, Shah Nirav, Mamoun Negmeldeen
Anesthesiology, Duke University Health System, Durham, North Carolina, USA.
Duke Molecular Physiology Institute, Duke University Hospital, Durham, North Carolina, USA.
BMJ Open Qual. 2024 Apr 24;13(2):e002726. doi: 10.1136/bmjoq-2023-002726.
Albumin continues to be used routinely by cardiac anaesthesiologists perioperatively despite lack of evidence for improved outcomes. The Multicenter Perioperative Outcomes Group (MPOG) data ranked our institution as one of the highest intraoperative albumin users during cardiac surgery. Therefore, we designed a quality improvement project (QIP) to introduce a bundle of interventions to reduce intraoperative albumin use in cardiac surgical patients.
Our institutional MPOG data were used to analyse the FLUID-01-C measure that provides the number of adult cardiac surgery cases where albumin was administered intraoperatively by anaesthesiologists from 1 July 2019 to 30 June 2022. The QIP involved introduction of the following interventions: (1) education about appropriate albumin use and indications (January 2021), (2) email communications reinforced with OR teaching (March 2021), (3) removal of albumin from the standard pharmacy intraoperative medication trays (April 2021), (4) grand rounds presentation discussing the QIP and highlighting the interventions (May 2021) and (5) quarterly provider feedback (starting July 2021). Multivariable segmented regression models were used to assess the changes from preintervention to postintervention time period in albumin utilisation, and its total monthly cost.
Among the 5767 cardiac surgery cases that met inclusion criteria over the 3-year study period, 16% of patients received albumin intraoperatively. The total number of cases that passed the metric (albumin administration was avoided), gradually increased as our interventions went into effect. Intraoperative albumin utilisation (beta=-101.1, 95% CI -145 to -56.7) and total monthly cost of albumin (beta=-7678, 95% CI -10712 to -4640) demonstrated significant decrease after starting the interventions.
At a single academic cardiac surgery programme, implementation of a bundle of simple and low-cost interventions as part of a coordinated QIP were effective in significantly decreasing intraoperative use of albumin, which translated into considerable costs savings.
尽管缺乏证据表明围手术期使用白蛋白能改善预后,但心脏麻醉医生仍在围手术期常规使用白蛋白。多中心围手术期结局研究组(MPOG)的数据显示,我们机构是心脏手术期间术中白蛋白使用量最高的机构之一。因此,我们设计了一个质量改进项目(QIP),引入一系列干预措施,以减少心脏手术患者术中白蛋白的使用。
我们使用机构的MPOG数据来分析FLUID-01-C指标,该指标提供了2019年7月1日至2022年6月30日期间麻醉医生在术中使用白蛋白的成人心脏手术病例数。QIP包括引入以下干预措施:(1)关于白蛋白适当使用和适应症的教育(2021年1月),(2)通过手术室教学加强电子邮件沟通(2021年3月),(3)从标准药房术中用药盘中移除白蛋白(2021年4月),(4)大查房报告讨论QIP并强调干预措施(2021年5月),以及(5)每季度向医疗服务提供者反馈(从2021年7月开始)。使用多变量分段回归模型评估干预前到干预后时间段内白蛋白使用情况及其每月总成本的变化。
在3年研究期间符合纳入标准的5767例心脏手术病例中,16%的患者术中接受了白蛋白治疗。随着我们的干预措施生效,达到指标(避免使用白蛋白)的病例总数逐渐增加。开始干预后,术中白蛋白使用量(β=-101.1,95%CI -145至-56.7)和白蛋白每月总成本(β=-7678,95%CI -10712至-4640)显著下降。
在一个学术性心脏手术项目中,实施一系列简单且低成本的干预措施作为协调的QIP的一部分,有效地显著减少了术中白蛋白的使用,这转化为可观的成本节约。